Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials
Ophthalmology and Therapy · 2025-12 · 14 (12) · 3119-3132
DOI: 10.1007/s40123-025-01255-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology and Therapy, online erschienen am 09.10.2025. Verfasst von Daniel Ezra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Moorfields Eye Hospital and University College London, London, UK. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
INTRODUCTION: Thyroid eye disease (TED) is a rare, autoimmune, orbital inflammatory disorder that is disfiguring, debilitating, and potentially sight-threatening. There is an unmet need for a fast-acting, durable, systemic disease-modifying therapy in active TED, for which current options are associated with relapses and side effects, and for chronic inactive TED, which is largely managed with surgery. Satralizumab is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody that prevents IL-6 from binding to its receptor, thereby reducing proinflammatory and profibrotic signaling. The SatraGO-1 and SatraGO-2 trials evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with active, moderate-to-severe, and chronic inactive TED. METHODS: SatraGO-1 and SatraGO-2 were two identically designed, 72-week, double-masked, placebo-controlled, multicenter, two-stage randomization, phase 3 trials in adults with active, moderate‑to‑severe TED or chronic inactive TED. Participants were randomized 1:1 to receive satralizumab or matching placebo. Based on the proptosis response assessed at week 24, nonresponders received satralizumab every 4 weeks (Q4W), while responders were rerandomized in a 1:1 ratio to receive satralizumab or placebo Q4W through week 44. The primary end point was the proportion of participants with active, moderate-to-severe TED who achieved ≥ 2-mm reduction in proptosis in the study eye from baseline at week 24. RESULTS: SatraGO-1 and SatraGO-2 enrolled 131 and 127 participants, respectively. CONCLUSIONS: The SatraGO-1 and SatraGO-2 trials investigated IL-6R inhibition via satralizumab in TED. Satralizumab offers a potential disease-modifying treatment option for TED while minimizing safety risks associated with current treatments. TRIAL REGISTRATION: SatraGO-1 (NCT05987423) and SatraGO-2 (NCT06106828).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Moorfields Eye Hospital and University College London, London, UK.
- Eye Medical Center of Fresno, Fresno, CA, USA.
- Genentech, Inc., South San Francisco, CA, USA.
- F. Hoffmann-La Roche Ltd., Basel, Switzerland.
- Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
- Genentech, Inc., South San Francisco, CA, USA. idowu.oluwatobi@gene.com.
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Ezra, D., Collins, A., Haskova, Z., Kuenzel, T., Ida, H., Triyatni, M., Brittain, C., & Idowu, O. (2025). Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials. Ophthalmology and Therapy, 14(12), 3119-3132. https://doi.org/10.1007/s40123-025-01255-3
Vancouver
Ezra D, Collins A, Haskova Z, Kuenzel T, Ida H, Triyatni M, et al. Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials. Ophthalmology and Therapy. 2025;14(12):3119-3132. doi:10.1007/s40123-025-01255-3
BibTeX
@article{Ezra2025,
author = {Ezra, Daniel and Collins, Atif and Haskova, Zdenka and Kuenzel, Thomas and Ida, Hiroaki and Triyatni, Miriam and Brittain, Christopher and Idowu, Oluwatobi},
title = {Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials},
journal = {Ophthalmology and Therapy},
year = {2025},
volume = {14},
number = {12},
pages = {3119--3132},
doi = {10.1007/s40123-025-01255-3}
}
EUVIMED